ACP
Acuta Capital Partners Portfolio holdings
AUM
$71.6M
This Quarter Return
-1.02%
1 Year Return
+169.78%
3 Year Return
+1,553.75%
5 Year Return
+4,509.01%
10 Year Return
+155,159.98%
AUM
$238M
AUM Growth
+$238M
(-15%)
Cap. Flow
-$23.3M
Cap. Flow
% of AUM
-9.8%
Top 10 Holdings %
Top 10 Hldgs %
62.29%
Holding
58
New
11
Increased
7
Reduced
11
Closed
21
Top Buys
| 1 |
Apellis Pharmaceuticals
APLS
|
$21.7M |
| 2 |
Relmada Therapeutics
RLMD
|
$9.1M |
| 3 |
Pyxis Oncology
PYXS
|
$7.44M |
| 4 |
Merus
MRUS
|
$3.61M |
| 5 |
Viridian Therapeutics
VRDN
|
$3.6M |
Top Sells
| 1 |
BLU
BELLUS Health Inc.
BLU
|
$11.9M |
| 2 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$11.1M |
| 3 |
Clearside Biomedical
CLSD
|
$7.9M |
| 4 |
Xenon Pharmaceuticals
XENE
|
$6.01M |
| 5 |
Cartesian Therapeutics
RNAC
|
$4.26M |
Sector Composition
| 1 | Healthcare | 92.25% |
| 2 | Financials | 5.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
United Therapeutics
UTHR
$17.7B
| – | – |
-3,000
| Closed | -$554K |
|
|
CMRX
52
DELISTED
Chimerix, Inc.
CMRX
| – | – |
-210,000
| Closed | -$1.3M |
|
|
VINC
53
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
| – | – |
-260,000
| Closed | -$4.2M |
|
|
CBAY
54
DELISTED
Cymabay Therapeutics
CBAY
| – | – |
-301,904
| Closed | -$1.1M |
|
|
RAIN
55
DELISTED
Rain Oncology Inc. Common Stock
RAIN
| – | – |
-182,500
| Closed | -$2.73M |
|
|
RETA
56
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| – | – |
-17,500
| Closed | -$1.76M |
|